John Hood

CRFMDDSWlIJuKYq8hE6yQckGOm4GFqDH7BBLbVeq.png

John Hood is the founder or co-founder of Aspera Biomedicines, Impact Biomedicines, Endeavor Biomedicines and Samumed. Currently John is Executive Chairman of Endeavor Biomedicines. Most recently he was the Founder and Chief Executive Officer of Impact Biomedicines, a company that was acquired for up to $7 billion by Celgene in 2018. Prior to founding Impact, Dr. Hood was the Co-Founder and Chief Scientific Officer of Samumed. Prior to that, Dr. Hood was Director of Research and co-inventor of fedratinib at TargeGen, Inc. He is an inventor on 100+ patents and author on 50+ scientific articles. Dr. Hood obtained a Ph.D. in medical physiology and B.S. in biochemistry from Texas A&M University.